Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Article content
Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers
Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP 2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions
Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates
Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates
Article content
Article content
VANCOUVER — DCx Biotherapeutics Corporation ('DCx') today announced an agreement with Repare Therapeutics Inc. ('Repare') (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the 'Transaction'). Combining the founding team's deep expertise in biologics innovation and development with the newly acquired discovery and translational capabilities, DCx is uniquely positioned to develop a new class of Multi-Modal Antibody Drug Conjugates ('MM-ADCs') against genetically-defined cancers.
Article content
DCx Strategy:
Article content
DCx addresses the root drivers of cancer, genetic mutations that lead to tumor proliferation and survival, by deconvoluting key cellular interdependencies using the MuSic™ platform. Understanding this roadmap enables the mutation-specific drugging of multiple critical targets to synergistically destroy tumors and induce long-term immune memory to achieve durable therapeutic responses while limiting side effects. Unlike current ADCs that deliver broadly chemotoxic payloads to a limited set of antibody targets, DCx's starting strategy is to develop MM-ADCs that optimize the synergy between, and simultaneously target, genetically-defined intracellular and cell-surface targets. The goals for this approach are to (i) increase efficacy, (ii) prolong activity by eliminating escape mechanisms and engaging the immune system, and (iii) improve tolerability while reducing side effects.
Article content
'DCx's founding vision is to realize the full potential of antibody drug conjugates by improving on the selectivity, potency, and tolerability for this promising class of therapeutics thus leading to improved clinical outcomes such as progression-free survival and overall survival,' said Ali Tehrani, PhD, Chief Executive Officer of DCx. 'This transaction with Repare is highly synergistic with our expertise and ambitions and accelerates the development of multiple development candidates over the next three years. We are also looking forward to embarking on this journey together with Repare's world-class preclinical research team that is joining the DCx family.'
Article content
Transaction:
Article content
DCx acquires rights to Repare's proprietary CRISPR, bioinformatics, and machine learning enabled platforms (now known collectively as the MuSic™ Platform) for the identification of surfaceome targets specific to genetic lesions in tumors
DCx obtains non-exclusive license to SNIPRx® and STEP 2 in support of discovering synthetic lethal and other targets
DCx acquires undisclosed surfaceome targets ('Acquired Targets') and antibodies discovered by Repare
DCx acquires undisclosed small molecule programs from Repare
DCx welcomes ~20 scientific and support colleagues spanning expertise in medicinal chemistry, molecular biology, bioinformatics, analytics, and pharmacology
DCx acquires lease rights to certain of Repare's Montreal laboratory facility and certain laboratory equipment
Article content
'We are excited with the potential in what DCx can bring to develop next-gen antibody drug conjugates and how this Transaction, together with a world-class management and scientific team, can meaningful propel these efforts forward,' comments Jean-François Pariseau, DCx Board Chair and Partner at Amplitude Ventures.
Article content
Launched out of Amplitude by Partner Ali Tehrani, DCx is the sixth company launched by Amplitude via its innovation platform. As part of this Transaction, Dr. Tehrani will assume the role of CEO. Other co-founders include Drs. David Poon and Ismael Samudio, and Ms. Candice Madalena. Together, they will leverage their deep experience in drug development, including most recently at Abdera and Zymeworks, which recently had the world's first bi-paratopic antibody therapeutic, Ziihera® (zanidatamab), approved by the FDA.
Article content
The Transaction is effective as of May 1, 2025. In consideration for the Transaction, Repare is eligible to receive, from DCX, the following:
Article content
Upfront and near-term cash payments, together with equity in DCx and a nominee to DCx's board of directors
Out-licensing, clinical, and commercial milestones, as well as low single-digit tiered sales royalties for products developed with Acquired Programs
Out-licensing, clinical, and commercial milestones for products developed with Acquired Targets
Article content
Other financial information is not disclosed.
Article content
DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precision antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit www.dcxbio.com to learn more.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Canada News.Net

an hour ago

• Canada News.Net

Wall Street ends with whimper as investors fret over Israel-Itan conflict

NEW YORK, New YorK - U.S. stocks closed mixed on Friday, with gains and losses modest, as investors and traders weighed up the escalation of hostilities in the Middle East, and President Donald Trump's prevarications over whether or not to involve the U.S. in another war. "With so much uncertainty going on in this world, who really wants to go long over the weekend," Sam Stovall, chief investment strategist at CFRA Research told CNBC Friday. "If there's a calming down of the geopolitical activities, then you know that could be helpful," he said. Major U.S. indexes ended Friday's trading session with mixed results as investors weighed economic data and corporate earnings ahead of the weekend. The tech-heavy Nasdaq led declines, while the Dow Jones managed modest gains. Technology stocks faced pressure following mixed earnings reports, while defensive sectors helped the Dow end in positive territory. Trading volumes were moderate, with the S&P 500 seeing 4.936 billion shares change hands. Analysts noted cautious sentiment ahead of next week's key inflation data and Federal Reserve commentary. Key Market Moves Global Forex Markets Wrap Up Friday with U.S. Dollar Back on Top Friday's foreign exchange session saw the U.S. dollar gaining against all the major currencies. Here's a breakdown of Friday's latest FX rates: Key Currency Pairs EUR/USD (Euro/US Dollar): Rose to 1.1521 up 0.24 percent as the euro strengthened slightly. USD/JPY (US Dollar/Japanese Yen): Climbed to 146.11, gaining 0.46 percent amid continued dollar strength. USD/CAD (US Dollar/Canadian Dollar): Increased to 1.3732, up 0.25 percent as oil-linked currencies faced pressure. GBP/USD (British Pound/US Dollar): Edged lower to 1.3453, dipping 0.09 percent in cautious trading. USD/CHF (US Dollar/Swiss Franc): Advanced to 0.8176, rising 0.15 percent as the franc softened. AUD/USD (Australian Dollar/US Dollar): Fell to 0.6450, down 0.47 percent on weaker risk sentiment. NZD/USD (New Zealand Dollar/US Dollar): Dropped to 0.5965, declining 0.44 percent in tandem with broader commodity FX weakness. Global Markets Wrap Up Friday with Mixed Performance Friday's trading session saw mixed results across global indices, with some markets posting gains while others edged lower. Here's a detailed look at the closing figures: European markets showed resilience, with Germany's DAX leading gains, while Asian indices were mixed amid varied regional economic signals. India's Sensex stood out with a strong rally, whereas Australia and New Zealand saw slight declines. Canada S&P/TSX Composite (Canada): Finished nearly flat at 26,497.57, slipping just 8.43 points (-0.03 percent). UK and Europe FTSE 100 (UK): Closed at 8,774.65, down 17.15 points (-0.20 percent). DAX (Germany): Rose sharply to 23,350.55, gaining 293.17 points (+1.27 percent). CAC 40 (France): Ended at 7,589.66, up 36.21 points (+0.48 percent). EURO STOXX 50: Advanced to 5,233.58, adding 36.55 points (+0.70 percent). BEL 20 (Belgium): Climbed to 4,439.53, increasing by 27.82 points (+0.63 percent). Asia and Pacific Hang Seng (Hong Kong): Jumped to 23,530.48, up 292.74 points (+1.26 percent). Nikkei 225 (Japan): Dipped to 38,403.23, down 85.11 points (-0.22 percent). SSE Composite (China): Closed at 3,359.90, slipping 2.21 points (-0.07 percent). STI (Singapore): Slipped to 3,883.43, losing 10.75 points (-0.28 percent). S&P/ASX 200 (Australia): Fell to 8,505.50, down 18.20 points (-0.21 percent). All Ordinaries (Australia): Dropped to 8,723.50, declining by 17.90 points (-0.20 percent). S&P BSE SENSEX (India): Surged to 82,408.17, gaining 1,046.30 points (+1.29 percent). IDX Composite (Indonesia): Declined to 6,907.14, down 61.50 points (-0.88 percent). KLSE (Malaysia): Inched up to 1,502.74, rising 1.30 points (+0.09 percent). NZX 50 (New Zealand): Fell to 12,569.05, losing 58.27 points (-0.46 percent). KOSPI (South Korea): Rose to 3,021.84, up 44.10 points (+1.48 percent). TWSE (Taiwan): Gained slightly to 22,045.74, adding 42.24 points (+0.19 percent). Middle East Middle East markets were mostly closed on Friday and will re-open on Sunday. Africa Johannesburg All Share (South Africa): Ended at 5,202.45, up 23.46 points (+0.45 percent).

Globe and Mail

5 hours ago

• Globe and Mail

Should You Buy Micron Stock Before June 25?

Micron (NASDAQ: MU) is scheduled to report quarterly financial results after the stock markets close on June 25, 2025. That has investors wondering if they should buy the semiconductor stock before the company announces its earnings results. *Stock prices used were the afternoon prices of June 18, 2025. The video was published on June 20, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Should you invest $1,000 in Micron Technology right now? Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of June 9, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Cision Canada

6 hours ago

• Cision Canada

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic ®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /CNW/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points *. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic ®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic ®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001) *. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group *. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was g enerally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no sever e hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba ®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin ®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin ® 30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.